BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 30539501)

  • 1. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.
    Hochmair MJ; Buder A; Schwab S; Burghuber OC; Prosch H; Hilbe W; Cseh A; Fritz R; Filipits M
    Target Oncol; 2019 Feb; 14(1):75-83. PubMed ID: 30539501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
    Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world data on treatment outcomes in
    Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
    Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
    Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
    Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis.
    Mitsuya S; Tsuruoka K; Kanaoka K; Funamoto T; Tsuji H; Matsunaga N; Nakamura T; Tamura Y; Imanishi M; Ikeda S; Fujisaka Y; Goto I; Imagawa A
    Anticancer Res; 2021 Oct; 41(10):5137-5145. PubMed ID: 34593465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors.
    Li C; Jia R; Liu H; Zhang B; Wang C
    Diagn Pathol; 2018 Aug; 13(1):49. PubMed ID: 30103780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer.
    Lee K; Kim D; Yoon S; Lee DH; Kim SW
    Eur J Cancer; 2021 May; 148():202-210. PubMed ID: 33744716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
    Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K
    Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
    Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
    Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib.
    Oya Y; Yoshida T; Asada K; Oguri T; Inui N; Morikawa S; Ito K; Kimura T; Kunii E; Matsui T; Kubo A; Kato T; Abe T; Tsuda T; Hida T
    BMC Cancer; 2021 Jan; 21(1):57. PubMed ID: 33435905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
    Takahama T; Azuma K; Shimokawa M; Takeda M; Ishii H; Kato T; Saito H; Daga H; Tsuboguchi Y; Okamoto I; Otsubo K; Akamatsu H; Teraoka S; Takahashi T; Ono A; Ohira T; Yokoyama T; Sakai K; Yamamoto N; Nishio K; Nakagawa K
    Cancer; 2020 Jan; 126(9):1940-1948. PubMed ID: 32022929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG).
    Popat S; Jung HA; Lee SY; Hochmair MJ; Lee SH; Escriu C; Lee MK; Migliorino MR; Lee YC; Girard N; Daoud H; Märten A; Miura S
    Lung Cancer; 2021 Dec; 162():9-15. PubMed ID: 34649106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib.
    Minari R; Leonetti A; Gnetti L; Zielli T; Ventura L; Bottarelli L; Lagrasta C; La Monica S; Petronini PG; Alfieri R; Tiseo M
    Anticancer Drugs; 2021 Aug; 32(7):758-762. PubMed ID: 33675607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M.
    Zhao S; Li X; Zhao C; Jiang T; Jia Y; Shi J; He Y; Li J; Zhou F; Gao G; Li W; Chen X; Su C; Ren S; Zhou C
    Lung Cancer; 2019 Feb; 128():33-39. PubMed ID: 30642450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.
    Boysen Fynboe Ebert E; McCulloch T; Holmskov Hansen K; Linnet H; Sorensen B; Meldgaard P
    Lung Cancer; 2020 May; 143():67-72. PubMed ID: 32213382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study).
    Eide IJZ; Helland Å; Ekman S; Mellemgaard A; Hansen KH; Cicenas S; Koivunen J; Grønberg BH; Brustugun OT
    Lung Cancer; 2020 May; 143():27-35. PubMed ID: 32200138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI.
    Chiang CL; Huang HC; Shen CI; Luo YH; Chen YM; Chiu CH
    Target Oncol; 2020 Aug; 15(4):503-512. PubMed ID: 32696212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of acquired resistance to afatinib clarified with liquid biopsy.
    Nakamura T; Nakashima C; Komiya K; Kitera K; Hirai M; Kimura S; Aragane N
    PLoS One; 2018; 13(12):e0209384. PubMed ID: 30550608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
    Liu Y; Li Y; Ou Q; Wu X; Wang X; Shao YW; Ying J
    Lung Cancer; 2018 Apr; 118():1-5. PubMed ID: 29571986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study.
    Minari R; Mazzaschi G; Bordi P; Gnetti L; Alberti G; Altimari A; Gruppioni E; Sperandi F; Parisi C; Guaitoli G; Bettelli S; Longo L; Bertolini F; Pagano M; Bonelli C; Tagliavini E; Nicoli D; Ubiali A; Zangrandi A; Trubini S; Proietto M; Fiorentino M; Tiseo M;
    Clin Lung Cancer; 2020 Sep; 21(5):e464-e473. PubMed ID: 32276870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.